The FDA's groundbreaking approval of the first natalizumab biosimilar heralds a new era in multiple sclerosis treatment, offering hope, affordability, and expanded access for patients.
Read MoreThe FDA's groundbreaking approval of the first natalizumab biosimilar heralds a new era in multiple sclerosis treatment, offering hope, affordability, and expanded access for patients.
Read More